|
Report Date : |
05.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
DONG KWANG PHARM CO., LTD. |
|
|
|
|
Registered Office : |
60, Myeong-dong 1-ga, Jung-gu, Seoul, Korea 100-021 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
02.11.1970 |
|
|
|
|
Com. Reg. No.: |
201-81-31347 |
|
|
|
|
Legal Form : |
Co., Ltd by Shares |
|
|
|
|
Line of Business : |
Manufacture of Finished Medicaments |
|
|
|
|
No. of Employees : |
415 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated
incredible growth and global integration to become a high-tech industrialized
economy. In the 1960s, GDP per capita was comparable with levels in the poorer
countries of Africa and Asia. In 2004, South Korea joined the trillion dollar
club of world economies, and is currently the world's 12th largest economy.
Initially, a system of close government and business ties, including directed
credit and import restrictions, made this success possible. The government
promoted the import of raw materials and technology at the expense of consumer
goods, and encouraged savings and investment over consumption. The Asian
financial crisis of 1997-98 exposed longstanding weaknesses in South Korea's
development model including high debt/equity ratios and massive short-term
foreign borrowing. GDP plunged by 6.9% in 1998, and then recovered by 9% in
1999-2000. Korea adopted numerous economic reforms following the crisis,
including greater openness to foreign investment and imports. Growth moderated
to about 4% annually between 2003 and 2007. Korea''s export focused economy was
hit hard by the 2008 global economic downturn, but quickly rebounded in
subsequent years, reaching 6.3% growth in 2010. The US-South Korea Free Trade
Agreement was ratified by both governments in 2011 and went into effect in
March 2012. Throughout 2012 the economy experienced sluggish growth because of
market slowdowns in the United States, China, and the Eurozone. The incoming
administration in 2013, following the December 2012 presidential election, is
likely to face the challenges of balancing heavy reliance on exports with
developing domestic-oriented sectors, such as services. The South Korean
economy''s long term challenges include a rapidly aging population, inflexible
labor market, and heavy reliance on exports - which comprise half of GDP.
Source
: CIA
|
Company
Name |
DONG KWANG PHARM
CO., LTD. (Korean Company
Name : “동광제약(주)”) |
|
Registered Address |
60, Myeong-dong 1-ga, Jung-gu, Seoul,
Korea |
|
Zip Code |
100-021 |
|
Tel |
+82-2-776-7641~2 |
|
Fax |
+82-2-777-4874 |
|
E-mail |
webmaster@dkpco.co.kr |
|
Website |
www.dkpco.co.kr |
|
Trading Address |
60, Myeong-dong 1-ga, Jung-gu, Seoul,
Korea |
|
Tel |
+82-2-776-7641~2 |
|
Fax |
+82-2-777-4874 |
|
Other Address |
439-1, Mogok-dong, Pyeongtaek-si,
Gyeonggi-do, Korea |
|
Tel |
+82-31-665-9761 |
|
Fax |
+82-31-665-9766 |
|
Type |
Export |
|
Industry |
Manufacture of Finished Medicaments |
|
Main Business |
Pharmaceuticals, Chemicals, Cosmetics |
|
Established (mm/dd/yyyy) |
11/02/1970 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs used for respiratory tract
disorders(51161700) |
|
Sell |
Antacids and antiflatulents(51171500) |
|
Sell |
Mirtazapine(51141604) |
|
Sell |
Dietary supplements and nutritional therapy
products(51191900) |
|
Sell |
Antidiarrheals(51171700) |
|
Sell |
Dental drugs(51212100) |
|
Sell |
Autonomic nervous system drugs(51150000) |
|
Sell |
Drugs affecting the gastrointestinal
system(51170000) |
|
Sell |
Antiasthmatic drugs(51161500) |
|
Sell |
Cough and cold and antiallergy
products(51161800) |
|
Buy |
Cefixime(51101599) |
|
Buy |
Nonsteroidal anti inflammatory drugs
NSAIDs(51142100) |
|
Buy |
Non narcotic analgesics and
antipyretics(51142000) |
|
Buy |
Oils(12181600) |
|
Buy |
Norfloxacin(51101546) |
|
Buy |
Ibuprofen(51142106) |
|
Buy |
Mefenamic acid(51142012) |
|
Buy |
Gliclazide(51181509) |
|
Buy |
Antiulcer and related gastrointestinal GI
drugs(51171900) |
|
Name |
Yu Byung-Kil |
|
Address |
179-20, Sinyeong-dong, Jongno-gu, Seoul,
Korea |
|
Date of Birth |
06/29/1942 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
3,450,000,000 |
|||||||||
|
Employees |
415 |
|||||||||
|
Formation |
Co., Ltd by Shares |
|||||||||
|
Bank Details |
Citi Bank-Daewoo center Branch |
|||||||||
|
Corporate Registered No. |
110111-0037708 |
|||||||||
|
Business Registered No. |
201-81-31347 |
|||||||||
|
Permit & Licenses |
07/2012 CE Mark Int’l Trade No.: 610672 |
|||||||||
|
Shareholder Position |
|
|||||||||
|
Company History |
08/1962 Established as DONG KWANG PHARM Research Co.(Sole Proprietorship) 11/02/1970 Incorporated as DONG KWANG PHARM CO., LTD.(“동광약품(주)”) 02/22/1973 changed company name to Gaeyang
Mulsan Co., Ltd. 01/1992 Changed company name to the present
name 11/2011 Awarded US$ 3 Million Export Top
Prize |
|||||||||
|
|
|
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Yu Byung-Kil |
Male |
Korean |
03/22/2002 |
|
Director |
Mr. |
Hong Soon-Young |
Male |
Korean |
10/08/2001 |
|
Director |
Mr. |
Kim Jin-Sung |
Male |
Korean |
06/17/2002 |
|
Director |
Mr. |
Kim Eui-Soo |
Male |
Korean |
10/01/2005 |
|
Director |
Mr. |
Lee Soon-Gyo |
Male |
Korean |
02/28/2008 |
|
Auditor |
Mr. |
Lim Jong-Ho |
Male |
Korean |
03/27/2000 |
|
Supervisor |
Mr. |
Han Cheol-Gyun |
Male |
Korean |
02/28/2008 |
|
Supervisor |
Mr. |
Kim Young-Hwan |
Male |
Korean |
10/14/2011 |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
78,386,394,711 |
126,501,465,690 |
12,297,149,956 |
|
|
2011 |
76,264,949,263 |
112,135,945,367 |
2,597,339,771 |
|
2010 |
75,658,025,443 |
109,873,723,210 |
4,008,534,401 |
|
Authorized Capital(KRW) |
5,000,000,000 |
|
Paid-Up Capital(KRW) |
3,450,000,000 |
|
Total Issued Shares |
690,000 |
Balance
Sheet
|
|||
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Total Assets |
126,501,465,690 |
112,135,945,367 |
109,873,723,210 |
|
Current Assets |
31,722,495,901 |
29,169,331,752 |
33,142,424,298 |
|
-Quick Assets |
23,625,412,463 |
20,643,017,506 |
27,692,777,512 |
|
-Inventories |
8,097,083,438 |
8,526,314,246 |
5,449,646,786 |
|
Fixed Assets |
94,778,969,789 |
82,966,613,615 |
76,731,298,912 |
|
-Investment |
34,924,638,524 |
22,581,192,194 |
16,816,250,454 |
|
-Tangibles |
57,499,391,582 |
55,631,298,462 |
55,384,641,864 |
|
-Intangibles |
1,349,991,734 |
1,327,864,606 |
1,131,589,341 |
|
-Others |
1,004,947,949 |
3,426,258,353 |
3,398,817,253 |
|
Total Liabilities |
86,219,850,923 |
81,094,817,322 |
81,429,934,936 |
|
Current Liabilities |
58,839,090,542 |
55,974,043,802 |
54,992,655,807 |
|
Fixed Liabilities |
27,380,760,381 |
25,120,773,520 |
26,437,279,129 |
|
Capital Stock |
3,450,000,000 |
3,450,000,000 |
3,450,000,000 |
|
Capital Surplus |
|
|
1,951,379,878 |
|
Profit Surplus |
-11,526,352,796 |
-23,625,949,377 |
-28,174,669,026 |
|
Capital Adjustment |
48,357,967,563 |
51,217,077,422 |
51,217,077,422 |
|
Total Equity |
40,281,614,767 |
31,041,128,045 |
28,443,788,274 |
|
Liab. & Shareholder’s Equity |
126,501,465,690 |
112,135,945,367 |
109,873,723,210 |
|
Current Liabilities |
58,839,090,542 |
55,974,043,802 |
54,992,655,807 |
|
Trade Payables |
12,109,465,278 |
12,460,399,450 |
13,620,184,354 |
|
Short-Term Borrowings |
30,906,543,342 |
30,867,555,421 |
29,698,845,818 |
|
Account Payables |
3,806,960,496 |
3,236,699,109 |
3,286,780,390 |
|
Withholdings |
4,229,038,191 |
3,817,290,643 |
3,824,780,553 |
|
Advance Receipts |
33,939,990 |
273,554,310 |
120,935,960 |
|
Accrued Expenses |
2,218,925,982 |
1,525,387,759 |
1,498,456,437 |
|
Accrued Income Tax |
2,690,426,626 |
47,158,797 |
641,903,790 |
|
Provisions for Refund |
316,912,638 |
512,097,983 |
729,449,359 |
|
Current Portion of Long-Term Debts |
2,526,877,999 |
3,000,800,000 |
1,375,000,000 |
|
Current Portion of Deferred Income Tax Credit |
- |
233,100,330 |
196,319,146 |
|
Fixed Liabilities |
27,380,760,381 |
25,120,773,520 |
26,437,279,129 |
|
Long-Term Borrowings |
3,446,537,657 |
999,200,000 |
2,000,000,000 |
|
Leasehold Deposit Received |
12,673,386,120 |
12,763,509,910 |
12,921,415,970 |
|
Provision for Severance & Retirement |
9,250,256,520 |
8,090,658,100 |
7,461,501,170 |
|
Non-Current Portion of Deferred Income Tax Credit |
5,779,551,723 |
6,553,558,962 |
6,773,022,761 |
Income
Statement
|
|||
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Sales |
78,386,394,711 |
76,264,949,263 |
75,658,025,443 |
|
Cost of Sold Goods |
37,452,671,658 |
32,979,417,091 |
28,806,690,183 |
|
Gross Profit |
40,933,723,053 |
43,285,532,172 |
46,851,335,260 |
|
Selling & Admin. Expenses |
37,657,293,799 |
38,938,687,824 |
39,650,149,586 |
|
Operating Income |
3,276,429,254 |
4,346,844,348 |
7,201,185,674 |
|
Non-Operating Income |
15,437,365,628 |
1,181,725,883 |
567,990,430 |
|
Non-Operating Expenses |
2,751,749,634 |
2,747,074,268 |
3,207,223,274 |
|
Income Before Taxes |
15,962,045,248 |
2,781,495,963 |
4,561,952,830 |
|
Income Taxes Expenses |
3,664,895,292 |
184,156,192 |
553,418,429 |
|
Net Income |
12,297,149,956 |
2,597,339,771 |
4,008,534,401 |
Cash
Flows
|
|||
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Cash Flows from Operating |
3,368,780,446 |
2,723,228,109 |
4,296,070,436 |
|
-Net Income |
12,297,149,956 |
2,597,339,771 |
4,008,534,401 |
|
-Exp. without Cash Outflow |
4,135,654,755 |
3,721,917,064 |
4,046,265,625 |
|
-Revenue without Cash Inflows |
-14,804,796,426 |
-761,240,740 |
- |
|
-Changes in Asset/ & Liability |
1,740,772,161 |
-2,834,787,986 |
-3,758,729,590 |
|
Cash Flows from Investing |
-2,679,063,399 |
-6,920,831,014 |
-1,824,844,681 |
|
-Cash Inflow from Investing |
2,508,938,410 |
537,335,555 |
845,920,645 |
|
-Cash Outflows for Investing |
-5,188,001,809 |
-7,458,166,569 |
-2,670,765,326 |
|
Cash Flows from Financing |
2,077,111,860 |
1,759,097,163 |
-271,602,047 |
|
-Cash Inflows from Financing |
50,308,202,143 |
11,207,997,720 |
19,263,137,529 |
|
-Cash Outflows from Financing |
-48,231,090,283 |
-9,448,900,557 |
-19,534,739,576 |
|
Increase/Decrease in Cash |
2,766,828,907 |
-2,438,505,742 |
2,199,623,708 |
|
Cash at the Beginning of Year |
596,071,303 |
3,034,577,045 |
834,953,337 |
|
Cash at the End of Year |
3,362,900,210 |
596,071,303 |
3,034,577,045 |
|
Main Products & Services |
Pharmaceuticals, Chemicals, Cosmetics |
|
Customers |
DALIM CORPRATION(110111-0998661) |
|
Competitors |
JEIL PHARMACEUTICAL CO., LTD.(110111-0026652) 745-5, BANPO 1-DONG, SEOCHO-GU, SEOUL, KOREA TEL:+82-2-549-7451 FAX:+82-2-549-7478 BORYUNG PHARM CO., LTD.(110111-0012560) 15TH FL., BORYEONG BLDG., 66-21, WONNAM-DONG, JONGNO-GU, SEOUL, KOREA TEL:+82-2-708-8000
FAX:+82-2-742-6362 KWANGDONG PHARMACEUTICAL CO., LTD(110111-0152134) 4TH FL., GASAN BLDG., 1577-4, SEOCHO
3-DONG, SEOCHO-GU, SEOUL, KOREA TEL:+82-2-6006-7777 FAX:+82-2-6006-702 |
(Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
CORYO INVESTMENT
CORPORATION(110111-0005903) (80.28% held by the subject company) |
|
Cooperative Enterprise |
-Insured Company DONGBU INSURANCE CO., LTD.(110111-0095285) |
(Activity &
Markets)
The Subject exports
to Myanmar, Vietnam and Hong Kong.
No.
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.80 |
|
|
1 |
Rs.91.95 |
|
Euro |
1 |
Rs.80.36 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.